Given that CD8 T cells are the main effector cells in anti-tumor responses, many studies have utilized next-generation sequencing and epitope prediction algorithms to identify and predict MHC class I (MHC-I)-restricted neoantigenomes. This evidence concerns the gene CD8A and neoplasm.